Board approve enabling resolution explore raising upto 600Cr
ORCHPHARMA 's Board met on October 20, 2026 and approved an enabling resolution to explore options for raising funds. Indicative size: up to Rs. 600 Crores (Rupees Six Hundred Crore Only). Possible routes: equity shares, other eligible securities or instruments, fully or partly convertible debentures, QIP, private placement, public issue of equity shares and/or debt securities, preferential issue or any ***** to statutory and regulatory approvals, and member approval where ***** filing states the required information is not available as on date. Size vs market cap: Rs 600 crore is ~11.2% of the stated market cap (Rs 5,351 cr), so a material capital raise but not a takeover-size event. Dilution risk: a primary-equity route at market prices could dilute existing shareholders by roughly the same order (single-digit to low-double-digit %), depending on issuance method and pricing. Promoter control: promoters hold 74.45% — preferential/private placement to promoters or allotment with promoter participation would preserve control but could further entrench promoter share; an open QIP or public issue would dilute promoter/public proportions depending on participation. Balance sheet/leverage trade-off: current debt-to-equity is low (0.2x). Raising the full amount as debt would materially increase leverage and financial risk, while equity issuance would conserve leverage but dilute earnings per share.



















